<DOC>
	<DOCNO>NCT00295958</DOCNO>
	<brief_summary>RATIONALE : The LMB-2 immunotoxin find tumor cell kill without harm normal cell . Vaccines make peptide may help body build effective immune response kill tumor cell . Giving LMB-2 immunotoxin together vaccine therapy may kill tumor cell . PURPOSE : This phase II trial study well give LMB-2 immunotoxin together vaccine therapy work treat patient metastatic melanoma remove surgery .</brief_summary>
	<brief_title>LMB-2 Immunotoxin Vaccine Therapy Treating Patients With Metastatic Melanoma That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective clinical response patient progressive , unresectable metastatic melanoma treat recombinant LMB-2 immunotoxin peptide vaccination comprise gp100:209-217 ( 210M ) antigen , MART-1:27-35 antigen , Montanide ISA-51 . Secondary - Determine change level CD4+ , CD25+ regulatory T cell peripheral blood treatment patient treat regimen . - Determine ability recombinant immunotoxin LMB-2 augment peptide vaccination patient . - Determine toxicity profile regimen patient . OUTLINE : Patients receive LMB-2 immunotoxin IV 30 minute twice day 1-3 . Patients receive peptide vaccination comprise gp100:209-217 ( 210M ) antigen emulsify Montanide ISA-51 subcutaneously ( SC ) , MART-1:27-35 vaccine emulsify Montanide ISA-51 SC day 4 , 5 , 6 , 24-27 ( course 1 ) . After week 8 , patient achieve tumor response may receive 1 additional course absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically absence disease progression . PROJECTED ACCRUAL : A total 26 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis metastatic melanoma Unresectable disease Progressive disease receive standard therapy ( e.g. , interleukin2 dacarbazine ) HLAA0201 positive Measurable disease The following allowed : Resectable local/regional disease Patients whose serum neutralize LMB2 tissue culture , due either antitoxin antimouseimmunoglobulin G antibody ( &gt; 75 % activity 1 ug/mL LMB2 ) Received LMB2 another trial PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy 3 month WBC ≥ 3,000/mm^3 Absolute lymphocyte count &gt; 500/mm^3 Platelet count ≥ 90,000/mm^3 Bilirubin ≤ 2.0 mg/dL ( ≤ 3.0 mg/dL patient Gilbert 's syndrome ) AST ALT ≤ 2.5 time normal Albumin ≥ 3.0 g/dL No hepatitis B surface antigen hepatitis C positivity Creatinine ≤ 1.4 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No ongoing active infection Ejection fraction ≥ 45 % echocardiogram thallium stress test ( patient &gt; 50 year age OR history cardiovascular disease ) LVEF ≥ 45 % No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No psychiatric illness social situation would preclude study compliance No uncontrolled illness No known HIV positivity No autoimmune disease No immunodeficiency No malignancy Must willing undergo leukapheresis PRIOR CONCURRENT THERAPY : See Disease Characteristics More 12 week since prior monoclonal antibody therapy More 3 week since prior concurrent systemic therapy cancer No concurrent chronic anticoagulant therapy No concurrent systemic steroid therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>skin cancer</keyword>
</DOC>